Novartis biotech AveXis will invest another $60 million and hire another 200 workers for the site it is building in Durham, North Carolina.
Just days after bad news about manufacturing wreaked havoc with Dr. Reddy’s shares, the drugmaker was able to report something positive.
Dr. Reddy’s, which has been struggling to bring a number of its key plants up to FDA standards, has been unable to learn from past mistakes.
The FDA uncovered data integrity issues at the Immunomedics plant in New Jersey where it makes the cancer drug for which it was issued a CRL.
Novartis has reupped with Recro Pharma's CMO for production of two drugs, plus other news.
A pair of Korean companies have teamed up to buy stem cell manufacturing facilities and other assets of a failed U.S. biotech.
Drug wholesaler McKesson was lashed in an FDA warning letter for shipments in which opioids had been replaced by OTC drugs.
Progenics last year picked up an FDA approval for its orphan radiotherapeutic. Now it has picked up a manufacturing facility to produce it in.
Immunomedics says it will meet with the FDA to discuss the CRL it got for manufacturing, while Teva has a new union agreement in place.
Dr. Reddy’s reported that its formulation plant in Bachupally, India, has been cited by the FDA with 11 violations.
